Rho kinase inhibitors block melanoma cell migration and inhibit metastasis

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2272-2284

  Sadok, Amine ^a   McCarthy, Afshan ^a   Caldwell, John ^a   Collins, Ian ^a   Garrett, Michelle D ^a   Yeo, Maggie ^a   Hooper, Steven ^b   Sahai, Erik ^b   Kuemper, Sandra ^a   Mardakheh, Faraz K ^a   Marshall, Christopher J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; AT13148; BLEBBISTATIN; CCT129254; LIM KINASE 1; LIM KINASE 2; MYOSIN ADENOSINE TRIPHOSPHATASE; MYOSIN LIGHT CHAIN; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG; PHENYLETHANOLAMINE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ACTIN FILAMENT; ARTICLE; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MELANOMA; MELANOMA CELL; MESENCHYME CELL; METASTASIS; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL MOTION; DRUG EFFECTS; GENETICS; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

2-HYDROXYPHENETHYLAMINE; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84938914887     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2156     Document Type: Article

References (42)

1. Vanharanta S, Massague J. Origins of metastatic traits. Cancer Cell 2013;24:410-21.
2. Hall A. Rho family GTPases. Biochem Soc Trans 2012;40:1378-82.
3. Rath N, OlsonMF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 2012;13:900-8.
4. Samuel MS, Lopez JI, McGhee EJ, Croft DR, Strachan D, Timpson P, et al. Actomyosin-mediated cellular tension drives increased tissue stiffness and beta-catenin activation to induce epidermal hyperplasia and tumor growth. Cancer Cell 2011;19:776-91.
5. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009;9:108-22.
6. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005;4:387-98.
7. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-56.
8. Sahai E, Marshall CJ.Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5:711-9.
9. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis 2009;26:273-87.
10. Wilkinson S, Paterson HF, Marshall CJ. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. NatCell Biol 2005;7:255-61.
11. Sanz-Moreno V, Gadea G, Ahn J, Paterson H, Marra P, Pinner S, et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008;135:510-23.
12. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997;389:990-4.
13. Sasaki Y, Suzuki M, Hidaka H. The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway. Pharmacol Ther 2002;93:225-32.
14. Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res 2012;72:5338-47.
15. Patel RA, Liu Y, Wang B, Li R, Sebti SM. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities. Oncogene 2014;33:550-5.
16. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, et al. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem 2010;53:2239-49.
17. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, et al. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res 2012;18:3912-23.
18. Gadea G, Sanz-Moreno V, Self A, Godi A,Marshall CJ. DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol 2008;18:1456-65.
19. Sanz-Moreno V, Gaggioli C, YeoM, Albrengues J,Wallberg F, Viros A, et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell 2011;20:229-45.
20. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: new insights and new therapies. J Invest Dermatol 2012;132:854-63.
21. Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol 2013;31:148-55.
22. Homet B, Ribas A. New drug targets in metastatic melanoma. J Pathol 2014;232:134-41.
23. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012;10:23.
24. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009;15:294-303.
25. Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK-and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 2006;16:1515-23.
26. Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012;481:85-9.
27. Saxty G, Woodhead SJ, Berdini V, Davies TG, Verdonk ML, Wyatt PG, et al. Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem 2007;50:2293-6.
28. Lin K, Lin J, Wu WI, Ballard J, Lee BB, Gloor SL, et al. An ATP-site on-off switch that restricts phosphatase accessibility of Akt. Sci Signal 2012;5: ra37.
29. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, et al. First-inman clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011;29:4688-95.
30. Hooper S, Gaggioli C, Sahai E. A chemical biology screen reveals a role for Rab21-mediated control of actomyosin contractility in fibroblast-driven cancer invasion. Br J Cancer 2010;102:392-402.
31. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR, et al. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 2003;299:1743-7.
32. Sanz-Moreno V, Marshall CJ. The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr Opin Cell Biology 2010; 22:690-6.
33. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010;188:11-9.
34. Yin Z, Sadok A, Sailem H, McCarthy A, Xia X, Li F, et al. A screen for morphological complexity identifies regulators of switch-like transitions between discrete cell shapes. Nat Cell Biol 2013;15:860-71.
35. Pinner S, Sahai E. Imaging amoeboid cancer cell motility in vivo. J Microsc 2008;231:441-5.
36. Pinner S, Jordan P, Sharrock K, Bazley L, Collinson L, Marais R, et al. Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. Cancer Res 2009;69:7969-77.
37. Shaulian E, Zauberman A, Ginsberg D, Oren M. Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol 1992;12: 5581-92.
38. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206.
39. Wolf K, Friedl P. Molecular mechanisms of cancer cell invasion and plasticity. Br J Dermatol 2006;154(Suppl 1):11-5.
40. Sauzeau V, Le Mellionnec E, Bertoglio J, Scalbert E, Pacaud P, Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001;88: 1102-4.
41. Tharaux PL, Bukoski RC, Rocha PN, Crowley SD, Ruiz P, Nataraj C, et al. Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. J Immunol 2003;171:96-105.
42. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 1999;9:136-45.